MedaPhor has issued a trading update for the 12 months to 31 Dec 2018, with our forecasts in-line. Revenues are expected to be between £5.3m and £5.4m (Cenkos est £5.4m) and pre-exceptional EBITDA is expected at around -£3m (Cenkos est -£3.0m). MedaPhor's cash balance at the end of the year was £5.5m (Cenkos est £5.0m), this follows the recent cash raise of £4.9m which will primarily be used to develop its Clinical AI software products. We maintain our Buy recommendation.
07 Jan 2019
Cenkos: MedaPhor Group Plc - In-line trading update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: MedaPhor Group Plc - In-line trading update
Intelligent Ultrasound Group Plc (IUG:LON) | 9.0 0 2.9% | Mkt Cap: 29.4m
- Published:
07 Jan 2019 -
Author:
Chris Donnellan -
Pages:
5
MedaPhor has issued a trading update for the 12 months to 31 Dec 2018, with our forecasts in-line. Revenues are expected to be between £5.3m and £5.4m (Cenkos est £5.4m) and pre-exceptional EBITDA is expected at around -£3m (Cenkos est -£3.0m). MedaPhor's cash balance at the end of the year was £5.5m (Cenkos est £5.0m), this follows the recent cash raise of £4.9m which will primarily be used to develop its Clinical AI software products. We maintain our Buy recommendation.